Alert: Automation World now enhanced for the iPad and iPhone. Watch a quick video preview
Greenfield
Factory Automation
Bassett
Batch Processing
Hand
Process Automation
Reynolds
Packaging Automation
Campbell
On the Edge
Download this free 97-page Batch Process Playbook loaded with industry expert advice on topics ranging from control systems, instrumentation, and industrial networks to energy management, security, and system upgrades.
Perspective
|

Pharma Collaboration, Reauthorization, Cheaper Costs Needed

Print Reprint
     
Jamie Hintlian is optimistic about the pharmaceutical industry.

“The industry/government collaboration on [federal] Quality by Design [guidelines] should finally start to manifest itself in specific new capabilities and processes,” says the pharma vice president for automation software vendor Aspen Technology Inc. (www.aspentech.com), Burlington, Mass.

The good news is, it’s win-win, Hintlian says. “Big pharma will see benefits in quality management, batches being right the first time, etc. Regulatory agencies will see NCE [new chemical entity] submissions made with a better process understanding.”

Better regulatory understanding comes through better evaluation tools. “As science evolves, so must methods used by regulatory agencies to review products developed by America’s biopharmaceutical research companies,” says Washington, D.C.-based Pharmaceutical Research and Manufacturers of America (PhRMA, www.phrma.org). “That is why reauthorization of the Prescription Drug User Fee Act (PDUFA) is a top PhRMA priority.” In 2012, Congress must reauthorize PDUFA to prevent disruptions in the new-medicines evaluation process.

ADVERTISEMENT

Regardless, prices rise. In a March 2012 report—“Rx Price Watch Report: Trends in Retail Prices of Prescription Drugs Widely Used by Medicare Beneficiaries, 2005 to 2009”—the AARP’s Public Policy Institutes says, “[Our] first look at retail prices for a combined set of [514] widely used prescription drugs finds that the cumulative change in retail prices was almost double the rate of inflation between 2005 through 2009.”

How does that affect a consumer taking a prescription drug long-term? “This translates into an increase in the annual cost of therapy of more than $1,000 over the same time period,” says the Washington, D.C.-based AARP (formerly American Association of Retired People, www.aarp.org). AARP attributes its findings entirely to drug price growth among brand and specialty drugs, which, the association says, “more than offset substantial price decreases among generic drugs."

C. Kenna Amos, [email protected] is an Automation World Contributing Editor. 

0

Add new comment

 

  NEWSLETTERS
Don’t miss intelligence crucial to your job and business!
Click on any newsletter to view a sample. Enter your email address below to sign up!

News Insights

News & Analysis

Product Insights

Latest Automation Products

Best of Blogs

Industrial Automation Columnists

Automation Focus

Sponsored white papers, videos and products

Continuous Processing

Oil & Gas, Chemical and More

Automation Skills

Improve Industry Skills

Industrial
Ethernet Review

Network Application of IE

On The Edge
Blog

Workforce Development

Factory Automation

Technology for Discrete Manufacturing

Food Bev & Pharma

Automation Applications & Trends

Global Edition

Global automation news

Each newsletter ranges in frequency from once per month to a few times per month at most.

 

The best of the essentials!
Secrets to Automation Project Success

Sign up to receive timely updates from our editors and download this FREE Automation Project Survival Guide. It’s packed with field-tested best practices from industry experts that can help make your next automation project a success.

x